Subject preferences for acne treatments containing adapalene gel 0.1%: Results of the MORE trial

Cutis

Volumn 78, Issue 1 SUPPL., 2006, Pages 26-33

  Cook Bolden, Fran ^a  

^a Skin Specialty Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; DERMATOLOGICAL AGENT; NAPHTHALENE DERIVATIVE;

ACNE VULGARIS; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; GEL; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PATIENT ATTITUDE; PHASE 4 CLINICAL TRIAL; PSYCHOLOGICAL ASPECT; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; CHILD; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GELS; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; PATIENT ACCEPTANCE OF HEALTH CARE; TREATMENT OUTCOME;

EID: 33748951175     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Yazici K, Baz K, Yazici AE, et al. Disease-specific quality of life is associated with anxiety and depression in patients with acne. J Eur Acad Dermatol Venereol. 2004;18:435-439.
2. Baldwin HE. The interaction between acne vulgaris and the psyche. Cutis. 2002;70:133-139.
3. Egan N, Loesche MC, Baker MM. Randomized, controlled, bilateral (split-face) comparison trial of the tolerability and patient preference of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis. 2001;68(suppl 4):20-24.
4. Hanna S, Sharma J, Klotz J. Acne vulgaris: more than skin deep. Dermatol Online J [serial online]. August 2003;9(3):8. Accessed March 2, 2006.
5. Gollnick H, Cunliffe W, Berson D, et al; Global Alliance to Improve Outcomes in Acne. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(suppl 1):S1-S37.
6. Poot F. How to be a happy dermatologist. Dermatol Psychosom. 2004;5:112-113.
7. Weiss J, Shavin J, Davis MW. Improving patient satisfaction and acne severity in patients with mild to moderate acne: the BEST study. Cutis. 2003;71:3-4.
8. Campbell JL Jr, Weiss JS. The results of the MORE trial: overview. Cutis. 2006;78(suppl 1):5-11.
9. Stein Gold L. The MORE trial: effectiveness of adapalene gel 0.1% in real-world dermatology practices. Cutis. 2006;78(suppl 1):12-18.
10. Wolf JE Jr. Safety and tolerability in the MORE trial. Cutis. 2006;78(suppl 1):19-25.
11. Kellett N, West F, Finlay AY. Conjoint analysis: a novel, rigorous tool for determining patient preferences for topical antibiotic treatment for acne, a randomized controlled trial. Br J Dermatol 2006;154:524-532.
12. Berson DS, Chalker DK, Harper JC, et al. Current concepts in the treatment of acne: report from a clinical roundtable. Cutis. 2003;72(suppl 1):5-13.
13. Koo J. How do you foster medication adherence for better acne vulgaris management? Skinmed. 2003;2:229-233.
14. Differin [package insert]. Fort Worth, Tex: Galderma Laboratories, LP; 2003.
15. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003;49(suppl3):S200-S210.
16. Thiboutot DM, Shalita AR, Yamauchi PS, et al, on behalf of the Differin Study Group. Combination therapy with adapalene gel 0.1% & doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. Skinmed. 2005;4:138-146.
17. Baker M, Tuley M, Busdiecker FL, et al. Adapalene gel 0.1% is effective and well tolerated in acne patients in a dermatology practice setting. Cutis. 2001;68(suppl 4):41-47.